SpyGlass Pharma, Inc. SGP
SpyGlass Pharma, Inc. (Nasdaq: SGP) is an ophthalmology drug developer. Its lead program, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is in Phase 3 for Open-angle glaucoma and ocular hypertension (IOP reduction at time of cataract surgery). Its next catalyst on record is BIM-IOL System: Complete enrollment in two registrational Phase 3 trials (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BIM-IOL System — Complete enrollment in two registrational Phase 3 trials (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BIM-IOL System | Open-angle glaucoma / ocular hypertension | device-combination | Phase 3 |
| BIM-DRS (Drug Ring System, bimatoprost) | Open-angle glaucoma / ocular hypertension (pseudophakic patients, retreatment) | device-combination | Pre-clinical |
Recent results and decisions
- Oct 19, 2026positive Positive 4-year first-in-human data (N=21 evaluable): 37% mean IOP reduction, 86% (18 of 21) off all drops, 90% kept >=20/25 BCDVA, no product-related AEs.
86% (18 of 21) of patients remained off all topical IOP-lowering drops
Filing - Oct 19, 2026positive SpyGlass Pharma announces positive 4-year interim data from first-in-human trial showing 37% IOP reduction with 86% of patients remaining off topical drops.
37% reduction in mean IOP across all three dose groups from 25.1 ± 2.5 mmHg at baseline post-washout to 15.9 ± 2.8 mmHg
Filing - Mar 9, 2026positive Positive 12-month Phase 1/2 results (N=104): IOP reduction 34% (78 mcg) and 42% (39 mcg) vs 35% timolol control; 98%/96% drop-free; no serious ocular AEs.
98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.